SARACATINIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H32ClN5O5
Molecular Weight	542.026
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCN(CCOC2=CC3=C(C(OC4CCOCC4)=C2)C(NC5=C(Cl)C=CC6=C5OCO6)=NC=N3)CC1

InChI

InChIKey=OUKYUETWWIPKQR-UHFFFAOYSA-N

InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)

HIDE SMILES / InChI

Molecular Formula	C27H32ClN5O5
Molecular Weight	542.026
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.alzforum.org/therapeutics/saracatinib | https://www.ncbi.nlm.nih.gov/pubmed/17064066 | https://www.ncbi.nlm.nih.gov/pubmed/25070546

Saracatinib (AZD0530) is an oral, dual inhibitor of c-Src/Abl kinases initially developed by AstraZeneca for the treatment of cancer. The drug was tested for many neoplasms and reached phase III for ovarian cancer (in combination with paclitaxel), however without demonstrating any significant effect. Sarcatinib is also tested in patients with Alzheimer's Disease (Phase II). Its effect on Alzheimer's Disease patients is explained by inhibition of another kinase, Fyn, which is highly expressed in brain.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Tyrosine-protein kinase SRC 19 Target ID: CHEMBL267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17064066	Inhibitor 8504	2.7 nM [IC50]
Tyrosine-protein kinase ABL 29 Target ID: CHEMBL1862 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17064066	Inhibitor 8504	30.0 nM [IC50]
Tyrosine-protein kinase FYN 7 Target ID: CHEMBL1841 Sources: http://www.alzforum.org/therapeutics/saracatinib	Inhibitor 8504	8.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 278 Sources: https://clinicaltrials.gov/ct2/show/NCT02167256	Primary		Phase II 1147	Unknown Approved Use Unknown
Ovarian cancer 160 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25070546	Primary		Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
149 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20805299	175 mg single, oral dose: 175 mg route of administration: Oral experiment type: SINGLE co-administered:		SARACATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1653 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20805299	175 mg single, oral dose: 175 mg route of administration: Oral experiment type: SINGLE co-administered:		SARACATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
39 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20805299	175 mg single, oral dose: 175 mg route of administration: Oral experiment type: SINGLE co-administered:		SARACATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
250 mg 1 times / day multiple, oral Highest studied dose Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	DLT: Leukopenia, Acute renal failure... Dose limiting toxicities: Leukopenia (grade 3, 14.3%) Acute renal failure (grade 3, 14.3%) Septic shock (grade 5, 14.3%) Asthenia (grade 3, 14.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/20805299
175 mg 1 times / day multiple, oral MTD Dose: 175 mg, 1 times / day Route: oral Route: multiple Dose: 175 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	Sources: https://pubmed.ncbi.nlm.nih.gov/20805299
200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	DLT: Febrile neutropenia, Respiratory failure... Dose limiting toxicities: Febrile neutropenia (grade 3, 14.3%) Respiratory failure (grade 5, 14.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/20805299

AEs

AE	Significance	Dose	Population
Acute renal failure	grade 3, 14.3% DLT	250 mg 1 times / day multiple, oral Highest studied dose Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299
Asthenia	grade 3, 14.3% DLT	250 mg 1 times / day multiple, oral Highest studied dose Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299
Leukopenia	grade 3, 14.3% DLT	250 mg 1 times / day multiple, oral Highest studied dose Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299
Septic shock	grade 5, 14.3% DLT, Disc. AE	250 mg 1 times / day multiple, oral Highest studied dose Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299
Febrile neutropenia	grade 3, 14.3% DLT	200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299
Respiratory failure	grade 5, 14.3% DLT, Disc. AE	200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20805299	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20805299

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 CYP2C8 1057 P-gp 1741 MRP1 116 OCT2 779 OCTN1 32 OCT3 159	OCTN2 59 OCT2 434 CYP2A1 2 CYP2A6 626 MATE1 182 CYP2A13 12 CYP2E1 729 OCT3 92 OCT1 393 CYP2B6 776 OCTN1 55 CYP2C19 1119 CYP1A2 1197 CYP3A5 446	P-gp 301 ABCG1 3

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24713129/	likely [IC50 201.8 uM]
MRP1 232	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22623106/	no
P-gp 1932	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/22623106/	no
OCTN1 32	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	yes [IC50 0.072 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	yes [IC50 0.9 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24713129/	yes [IC50 46 uM]
OCT3 161	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	yes [IC50 50 uM]
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	yes [IC50 57 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	yes [Inhibition 33 uM]	M1 13
ABCG1 3	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/31931755/	yes
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22623106/	yes

Drug as victim

Target	Modality	Activity
CYP2A13 12	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	likely
CYP2A6 626	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	likely
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	likely
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	likely
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	likely
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	likely
MATE1 182	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	likely
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	major
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	minor
CYP2A1 2	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	minor
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	minor
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27769111/	unlikely
OCTN2 59	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	weak
OCT1 393	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	yes
OCT2 434	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	yes
OCT3 92	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	yes
OCTN1 55	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28455521/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY116334	https://www.001chemical.com/chem/search?q=DY116334
1PlusChem LLC	1P003A69	https://www.1pchem.com/search?query=1P003A69
AChemBlock	10283	http://www.achemblock.com/catalogsearch/result/?q=10283
AK Scientific	SYN5342	https://aksci.com/item_detail.php?cat=SYN5342
AK Scientific	X2639	https://aksci.com/item_detail.php?cat=X2639
AK Scientific	Y1467	https://aksci.com/item_detail.php?cat=Y1467
ApexBio Technology	A2133	https://www.apexbt.com/catalogsearch/result/?q=A2133
AstaTech	41081	http://astatechinc.com/CPSResult.php?CRNO=41081
Axon MedChem	1456	https://www.axonmedchem.com/product/1456
BioSynth	Q-201699	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201699
BLD Pharm	BD157890	http://www.bldpharm.com/search/Search.html?keyword=BD157890
BOC Sciences	379231-04-6	http://www.bocsci.com/description.asp?cas=379231-04-6
BOC Sciences	893428-72-3	http://www.bocsci.com/description.asp?cas=893428-72-3
Capot Chemical	25886	https://www.capotchem.com/search.do?q=25886
Cayman Chemical	11497	http://www.caymanchem.com/app/template/Product.vm/catalog/11497
Chem Scene	CS-0101	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0101
ChemShuttle	104920	https://www.chemshuttle.com/catalogsearch/result/?q=104920
Combi-Blocks	QJ-1835	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-1835
eMolecules	31593305	https://orderbb.emolecules.com/search/#?query=31593305
eMolecules	36367092	https://orderbb.emolecules.com/search/#?query=36367092
eMolecules	44848336	https://orderbb.emolecules.com/search/#?query=44848336
eNovation Chemicals	D372500	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372500&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A1576	http://www.excenen.com/searchresultlist.php?id=EX-A1576
KeyOrganics	AS-16692	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16692
Lab Seeker	SC-22885	http://www.labseeker.com/search.php?keywords=SC-22885&category=0
LabSeeker	SC-22885	http://www.labseeker.com/search.php?keywords=SC-22885&category=0
Matrix Scientific	145261	http://www.matrixscientific.com/145261.html
mcule	MCULE-4219101590	https://mcule.com/MCULE-4219101590/
MedChem Express	HY-10234	https://www.medchemexpress.com/search.html?q=HY-10234&ft=&fa=&fp=
Molcore	MC116334	http://www.molcore.com/CatMC116334.html
Molnova	M14308	https://www.molnova.com/en/serch-list.html?keywords=M14308
MolPort	MolPort-008-155-961	https://www.molport.com/shop/molecule-link/MolPort-008-155-961
MolPort	MolPort-035-706-616	https://www.molport.com/shop/molecule-link/MolPort-035-706-616
MuseChem	I003391	https://www.musechem.com/product/I003391.html
Selleck Chemicals	S1006	http://www.selleckchem.com/search.html?searchDTO.searchParam=S1006
ShangHai Biochempartner	BCP000078	http://www.biochempartner.com/search_BCP000078
ShangHai Biochempartner	BCP01733	http://www.biochempartner.com/search_BCP01733
TargetMol	T6078	https://www.targetmol.com/search?keyword=T6078
Tetrahedron	TS73118	http://www.thsci.com/search.do?q=TS73118
Toronto Research Chemicals	B288463	https://www.trc-canada.com/product-detail/?CatNum=B288463
Toronto Research Chemicals	S139350	https://www.trc-canada.com/product-detail/?CatNum=S139350

PubMed

Title	Date	PubMed
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.	2010-11	21115886
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.	2010-10-01	20805299
[SRC kinases in tumor therapy].	2010-10	20981590
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.	2010-08-15	20682712
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.	2010-08	20557276
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.	2010-07-15	20551056
Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.	2010-07	20683035
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.	2010-06	20484016
A novel bile acid-activated vitamin D receptor signaling in human hepatocytes.	2010-06	20371703
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.	2010-03	19775203
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.	2009-06-15	19509160
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.	2009-06	19393585
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.	2009-06	19293266
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.	2009-05-15	19451593
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.	2009-05	18493848
The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.	2009-04	19372577
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.	2009-04	19240653
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.	2009-03	19396016
Quantification of focal adhesion kinase activation loop phosphorylation as a biomarker of Src activity.	2009-03	19098120
Src inhibitors in early breast cancer: a methodology, feasibility and variability study.	2009-03	18409068
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.	2009-02-13	19216789
Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.	2009-02	19235590
Src as a therapeutic target in men with prostate cancer and bone metastases.	2009-02	19154462
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.	2009-02	19060248
Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.	2009-01-15	18924149
Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.	2009-01-01	19117998
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.	2008-10-23	18679417
Research provides new hope for tamoxifen-resistant breast cancer patients.	2008-03	19072510
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.	2006-12	17172405
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.	2006-11-02	17064066
Clinical development of SRC tyrosine kinase inhibitors in lung cancer.	2006-05	16800962

Patents

Sample Use Guides

In Vivo Use Guide

Alzheimer's Disease: patients receive 100-125 mg daily. Ovarian cancer: patients receive 175 mg once daily in combination with paclitaxel (80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks)).

Route of Administration: Oral

In Vitro Use Guide

Ovarian cancer cell lines (OVCA420, TOV112D, DOV13, A2780, EFO27, SKOV3, PEO1, OV167, Hey, OVCAR8, MCAS, ES2, OVCAR5) were exposed to increasing concentrations of saracatinib (ranging from 0–10 uM).

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:04:42 GMT 2025` Edited by `admin` on `Wed Apr 02 07:04:42 GMT 2025`
Record UNII	9KD24QGH76
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SARACATINIB

Official Name

English

4-QUINAZOLINAMINE, N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-(2-(4-METHYL-1-PIPERAZINYL)ETHOXY)-5-((TETRAHYDRO-2H-PYRAN-4-YL)OXY)-

Preferred Name

English

SARACATINIB [USAN]

Common Name

English

saracatinib [INN]

Common Name

English

AZD0530

Code

English

AZD-0530

Code

English

Saracatinib [WHO-DD]

Common Name

English

N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-(2-(4-METHYLPIPERAZIN-1-YL)ETHOXY)-5-((OXAN-4-YL)OXY)QUINAZOLIN-4-AMINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1967